Posters

Title Date Documents

RXi Q1 2017 Earnings Conference Call Transcript

2016 Annual Report

A Phase 1/2 Multidose, Dose Escalation Study to Evaluate RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects with Advanced Neovascular AMD (NVAMD) #3210

Targeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA) Technology - Presented at: Cavendish Global Impact Forum

Targeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA®) Technology - Presented at: TIDES

Prevention of UVR Induced MMP1 Upregulation-MMP1 Targeting sd-rxRNA May Reduce the Effects of Skin Photo-aging - Presented at Society of Investigative Dermatology

Topical Application of sd-rxRNA Compounds for Reduction of Hyperpigmentation - Presented at the Society of Investigative Dermatology

Enhancement of CAR T Cell Activity via PD-1 Silencing with sd-rxRNA® Self-Delivering RNAi Compounds - Presented at: American Association for Cancer Research (AACR) Annual Meeting

RXi Q4 and Year End 2014 Earnings Conference Call Transcript

RXi Q4 and Year End 2016 Earnings Conference Call Transcript